Evidence map›Paper›PMID 27412454›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis.

Agnieszka Blazejczyk, Marta Switalska, Stefan Chlopicki, Andrzej Marcinek, Jerzy Gebicki, Marcin Nowak, Anna Nasulewicz-Goldeman, Joanna Wietrzyk

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. NicotinamideBiomolecules · 2021
    Review
  7. A derivative of vitamin BScientific reports · 2021
    Article
  8. Article
  9. Article
  10. Skin cancer management-updates on Merkel cell carcinoma.Annals of translational medicine · 2018
    Review
  11. Alterations in NO- and PGIBMC cancer · 2018
    Article
  12. Article
  13. Comparison of Pulmonary and Systemic NO- and PGIOxidative medicine and cellular longevity · 2018
    Article
  14. Article
  15. Article
  16. NicotinamideInternational journal of tryptophan research : IJTR · 2017
    Review
  17. Functional and Biochemical Endothelial ProfilingFrontiers in pharmacology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Agnieszka BlazejczykHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
Marta SwitalskaHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
Stefan ChlopickiChair of Pharmacology, Jagiellonian University, Medical College, Grzegórzecka 16, 31-531, Krakow, Poland.
Andrzej MarcinekLodz University of Technology, Zeromskiego 116, 90-924, Lodz, Poland.
Jerzy GebickiLodz University of Technology, Zeromskiego 116, 90-924, Lodz, Poland.
Marcin NowakWroclaw University of Environmental and Life Sciences, Norwida 31, 50-375, Wroclaw, Poland.
Anna Nasulewicz-GoldemanHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland.
Joanna WietrzykHirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland. wietrzyk@iitd.pan.wroc.pl.
Lodz University of Technology · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLPolish Academy of Sciences · PLJagiellonian University · PLWroclaw University of Environmental and Life Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background1-methylnicotinamide (1-MNA), an endogenous metabolite of nicotinamide, has recently gained interest due to its anti-inflammatory and anti-thrombotic activities linked to the COX-2/PGI2 pathway. Given the previously reported anti-metastatic activity of prostacyclin (PGI2), we aimed to assess the effects of 1-MNA and its structurally related analog, 1,4-dimethylpyridine (1,4-DMP), in the prevention of cancer metastasis.

methodsAll the studies on the anti-tumor and anti-metastatic activity of 1-MNA and 1,4-DMP were conducted using the model of murine mammary gland cancer (4T1) transplanted either orthotopically or intravenously into female BALB/c mouse. Additionally, the effect of the investigated molecules on cancer cell-induced angiogenesis was estimated using the matrigel plug assay utilizing 4T1 cells as a source of pro-angiogenic factors.

resultsNeither 1-MNA nor 1,4-DMP, when given in a monotherapy of metastatic cancer, influenced the growth of 4T1 primary tumors transplanted orthotopically; however, both compounds tended to inhibit 4T1 metastases formation in lungs of mice that were orthotopically or intravenously inoculated with 4T1 or 4T1-luc2-tdTomato cells, respectively. Additionally, while 1-MNA enhanced tumor vasculature formation and markedly increased PGI2 generation, 1,4-DMP did not have such an effect. The anti-metastatic activity of 1-MNA and 1,4-DMP was further confirmed when both agents were applied with a cytostatic drug in a combined treatment of 4T1 murine mammary gland cancer what resulted in up to 80 % diminution of lung metastases formation.

conclusionsThe results of the studies presented below indicate that 1-MNA and its structural analog 1,4-DMP prevent metastasis and might be beneficially implemented into the treatment of metastatic breast cancer to ensure a comprehensive strategy of metastasis control.

Indexed as

AnimalsCadherinsCdh1 ProteinsCell Line, TumorEpoprostenolFemaleGene Expression Regulation, NeoplasticLung NeoplasmsMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CNiacinamidePyridinium CompoundsXenograft Model Antitumor AssaysCadherinsCdh1 ProteinsCdh2 protein, mouseEpoprostenolFzr1 protein, mouseN(1)-methylnicotinamideNiacinamidePyridinium Compounds1,4-dimethylpyridinium chloride1-methylnicotinaimide chlorideAngiogenesisBreast cancerCombined therapyMetastasis

Identifiers

PMID27412454
PMCPMC4944260
OpenAlexW2472843965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.